Viridian Therapeutics, Inc. VRDN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s investing cash flow?
- Viridian Therapeutics, Inc. (VRDN) reported investing cash flow of $77.26M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Viridian Therapeutics, Inc.'s investing cash flow decreased by 22.8% year-over-year, from $100.06M to $77.26M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s investing cash flow?
- Over 3 years (2021 to 2025), Viridian Therapeutics, Inc.'s investing cash flow has grown at a -20.3% compound annual growth rate (CAGR), from -$74.29M to -$37.56M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.